Shanghai Junshi Biosciences Co., Ltd. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (5)

Latest Posts

About This Stock More About This Stock
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Article By: ChinaBio® Today
Saturday, November 4, 2023 3:00 PM EDT
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have rights to manufacture and commercialize the drug.
In this article: MKGAF, BLRX, CHRS, IVBXF, SHJBF Also: LLY

Latest Tweets for $SHJBF

No tweets yet!